Heron Therapeutics Inc  

(Public, NASDAQ:HRTX)   Watch this stock  
Find more results for NASDAQ:APPA
18.12
+0.17 (0.95%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.04 - 18.50
52 week 9.06 - 42.25
Open 18.48
Vol / Avg. 712,243.00/844,268.00
Mkt cap 633.10M
P/E     -
Div/yield     -
EPS -2.78
Shares 35.97M
Beta 1.01
Inst. own 124%
Mar 11, 2016
Q4 2015 Heron Therapeutics Inc Earnings Release (Estimated) Add to calendar
Feb 10, 2016
Heron Therapeutics Inc at Leerink Partners Global Healthcare Conference
Nov 18, 2015
Heron Therapeutics Inc at Jefferies Autumn Global Healthcare Conference
Nov 16, 2015
Heron Therapeutics Inc at Brean Capital Life Sciences Summit Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -54.35% -100.08%
Return on average equity -60.31% -115.70%
Employees 59 -
CDP Score - -

Address

123 Saginaw Dr
REDWOOD CITY, CA 94063-4717
United States - Map
+1-650-3662626 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company's product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Company's other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.

Officers and directors

Kevin C. Tang Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Robert H. Rosen President, Director
Age: 59
Bio & Compensation  - Reuters
Barry D. Quart Pharm.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Brian G Drazba Chief Financial Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Neil James Clendeninn M.D., Ph.D. Senior Vice President and Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Paul G. Marshall Senior Vice President - Technical Operations
Age: 55
Bio & Compensation  - Reuters
Esme C. Smith Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Stephen R. Davis Director
Age: 54
Bio & Compensation  - Reuters
Craig A Johnson Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Poyhonen Independent Director
Age: 55
Bio & Compensation  - Reuters